Abuse of buprenorphine in the United States: 2003-2005

Journal of Addictive Diseases

Volumn 26, Issue 3, 2007, Pages 107-111

  Smith, Meredith Y ^a   Bailey, J Elise ^b   Woody, George E ^c   Kleber, Herbert D ^d  

^a PURDUE PHARMA L P   (United States)

^b Rocky Mountain Poison Control Center   (United States)

^c TREATMENT RESEARCH INSTITUTE   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Buprenorphine naloxone; Opioid analgesics; Opioid dependence; Prescription drug abuse; Sublingual buprenorphine; Suboxone ; Substitution therapy; Subutex

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE;

ARTICLE; DRUG ABUSE; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; POISON CENTER; STATISTICAL ANALYSIS;

ADMINISTRATION, SUBLINGUAL; ADULT; BUPRENORPHINE; FEMALE; HUMANS; MALE; NARCOTICS; OPIOID-RELATED DISORDERS; REGISTRIES;

EID: 34548433490     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v26n03_12     Document Type: Article

References (17)

1. Costa e Silva JA. Medicines and the drug control treaties: Is buprenorphine for opioid addiction at risk of being lost? Hum Psychopharmacol Clin Exp 2004;19:215-224.
2. Drug Addiction Treatment Act of 2000, Public Law 106-310, Title XXXV (DATA, 2000). Federal Food, Drug, and Cosmetic Act. (Act) 21 U.S.C. § 360, Section 510.
3. U.S. Food and Drug Administration. FDA Talk Paper: Subutex® and Suboxone® approved to treat opioid dependence. T08-38; October, 8. 2002. Available at: http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01165.hjtml. Last accessed: November 15, 2006.
4. Tzchenske TM. Behavioral pharmacology of burprenorphine with a focus on preclinical models of reward and addiction. Psychopharmacology 2002;161:1-16.
5. Auriacombe M, Fatsea M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. Am J Addict 2001;13(Suppl. 1):S17-28.
6. Guichard A, Lert F, Calderon C, Gaigi H, Maguet O, Soletti J, Brodeur J-M, Richard L, Benigeri M, Zunzunegui M-V. Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France. Addiction 2003;98:1585-1597.
7. Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 2005;100:197-205.
8. Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti J-P. Injecting misuse of buprenorphine among French drug users. Addiction 2001; 96: 267-272.
9. Parfitt T. Designer drug Subutex takes its toll in Tbilisi. Lancet 2006; 368: 273-274.
10. Winslow M, Ng W-L, Mythily S, Song G, Yiiong H-C. Socio-demographic profile and help-seeking behavior of buprenorphine abusers in Singapore. Ann Acad Med Singapore 2006;35:451-456.
11. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2006;22:533-541.
12. Smith MY, Dart R, Hughes A, Geller A, Senay E, Woody G, Colucci S. Clinician validation of poison control center (PCC) intentional exposure cases involving prescription opioids. Am J Drug Alcohol Abuse 2006;32:465-478.
13. IMS Health Inc., Xponent Database-in retail pharmacies and mail order, 2003-2005.
14. Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C. College on problems of drug dependence taskforce on prescription opioid non-medical use and abuse: Position statement. Drug Alcohol Depend 2003;69:215-232.
15. Substance Abuse and Mental Health Administration, Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) 40, 2004. Available at www.kap.samhsa.gov. (Last accessed, 04/13/07).
16. Strain EC, Stoller KM, Walsh SL, Bigelow GE. The effects of buprenorphine and buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology 2000;148:374-383.
17. Subutex®, Suboxone®. [package insert]. Reckitt-Benickser Pharmaceuticals. Richmond, VA.